Phase I/II clinical trial - VADS
DEBIO 1143-201
VADS
Essai clinique fermé
Public cible
Adulte
A Phase I/II randomised study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio 1143 combined with concurrent chemo-radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Description de l'essai
This randomized double-blinded phase II trial involves inoperable head and neck cancer patients who should be treated with chemoradiotherapy with cisplatin. These patients will take an oral targeted therapy during radiotherapy with the aim to improve efficacy of chemoradiotherapy.
Liens utiles
CHRISTOPHE LE TOURNEAU
Investigateur principal